ACD-856 is under clinical development by AlzeCure Pharma and currently in Phase I for Depression. According to GlobalData, Phase I drugs for Depression have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACD-856’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACD-856 overview
ACD-856 is under development for the treatment of Alzheimer's disease, sleeping disorders, traumatic brain injury, cognitive disorders, depression and Parkinson's disease. It is developed based on NeuroRestore platform. It acts by targeting Trk A and Trk B which enhances the effects of the endogenous neuronal growth factors NGF and BDNF. It is administered orally and intravenously.
AlzeCure Pharma overview
AlzeCure Pharma (AlzeCure) is a pharmaceutical company that develops innovative drug therapies for treating severe diseases. The company’s pipeline products include ACD856 targets alzheimer’s disease, traumatic brain injuries, parkinson’s disease, sleep disorders and depression; ACD680, ACD679 and ACD857 treat Alzheimer’s disease; ACD440 for neuropathic pain; and ACD137 treat osteoarthritic pain and other severe pain. The company will develop and conduct research of its projects to the early clinical phase and try to find suitable out-licensing solutions with other pharmaceutical companies for its products. AlzeCure is headquartered in Huddinge, Sweden.
For a complete picture of ACD-856’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
